IN8bio Q4 net loss narrows, cash position more than doubles

Overview

• US biopharma firm's Q4 net loss narrowed yr/yr as cash position more than doubled

• Company closed $20.1 mln tranche of private placement, extending cash runway into H1 2027

Outlook

• Company expects cash runway to extend into first half of 2027

• IN8bio anticipates FDA guidance on regulatory pathway by second half of 2026

• Company expects multiple clinical and preclinical milestones in 2026

Result Drivers

• R&D expenses were $2.6 million for the three months ended December 31, 2025, compared with $3.6 million for the comparable prior year period

• As of December 31, 2025, the Company had cash of $27.1 million, compared with $11.1 million as of December 31, 2024

• LOWER OPERATING EXPENSES - Reduced R&D and G&A expenses contributed to a narrower net loss yr/yr

• PRIVATE PLACEMENT - Closing of $20.1 mln tranche extended cash runway and supported advancement of clinical programs

Company press release: ID:nGNXHwJq2

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for IN8bio Inc is $7.50, about 276.9% above its March 11 closing price of $1.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.